Shire (SHPG) Days Payable : 311.90 (As of Sep. 2018)

View and export this data going back to 1998. Start your Free Trial

What is Shire Days Payable?

Shire's average Accounts Payable for the three months ended in Sep. 2018 was $3,957 Mil. Shire's Cost of Goods Sold for the three months ended in Sep. 2018 was $1,158 Mil. Hence, Shire's Days Payable for the three months ended in Sep. 2018 was 311.90.

The historical rank and industry rank for Shire's Days Payable or its related term are showing as below:

SHPG's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 151.69
* Ranked among companies with meaningful Days Payable only.

Shire's Days Payable declined from Sep. 2017 (351.39) to Sep. 2018 (311.90). It may suggest that Shire accelerated paying its suppliers.

Shire Days Payable Historical Data

The historical data trend for Shire's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Days Payable Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Days Payable

Get a 7-Day Free Trial

111.74

83.92

129.78

64.71

70.91

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Days Payable	Get a 7-Day Free Trial															351.39	172.79	195.55	322.23	311.90

Competitive Comparison of Shire's Days Payable

For the Biotechnology subindustry, Shire's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shire's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Days Payable distribution charts can be found below:

* The bar in red indicates where Shire's Days Payable falls into.

Shire Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Shire's Days Payable for the fiscal year that ended in Dec. 2017 is calculated as

	Days Payable (A: Dec. 2017 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2016 )	+	Accounts Payable (A: Dec. 2017 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2017 )	*	Days in Period
=	( (911.9	+	914.6)	/	2 )	/	4700.8	*	365
=	913.25					/	4700.8	*	365
=	70.91

Shire's Days Payable for the quarter that ended in Sep. 2018 is calculated as:

	Days Payable (Q: Sep. 2018 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2018 )	+	Accounts Payable (Q: Sep. 2018 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2018 )	*	Days in Period
=	( (3888.5	+	4025.1)	/	2 )	/	1157.6	*	365 / 4
=	3956.8					/	1157.6	*	365 / 4
=	311.90

Shire Days Payable Related Terms

Thank you for viewing the detailed overview of Shire's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (SHPG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Executives

James H Cavanaugh

director

265 HOTHORPE LANE, VILLANOVA PA 19085